{"protocolSection":{"identificationModule":{"nctId":"NCT03172975","orgStudyIdInfo":{"id":"H-38292"},"secondaryIdInfos":[{"id":"U01AI129789","type":"NIH","link":"https://reporter.nih.gov/quickSearch/U01AI129789"}],"organization":{"fullName":"Baylor College of Medicine","class":"OTHER"},"briefTitle":"Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection","officialTitle":"Phase 2 Study to Assess the Safety, Efficacy and Immunogenicity of Na-GST-1/Alhydrogel Co-administered With Different Toll-Like Receptor Agonists in Hookworm- Naïve Adults"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-03-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-12-31","type":"ACTUAL"},"completionDateStruct":{"date":"2025-01-30","type":"ACTUAL"},"studyFirstSubmitDate":"2017-05-30","studyFirstSubmitQcDate":"2017-05-30","studyFirstPostDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-09-08","resultsFirstSubmitQcDate":"2025-12-02","resultsFirstPostDateStruct":{"date":"2025-12-05","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-27","lastUpdatePostDateStruct":{"date":"2026-03-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Maria Elena Bottazzi PhD","investigatorTitle":"Principal Investigator","investigatorAffiliation":"Baylor College of Medicine"},"leadSponsor":{"name":"Baylor College of Medicine","class":"OTHER"},"collaborators":[{"name":"George Washington University","class":"OTHER"},{"name":"National Institute of Allergy and Infectious Diseases (NIAID)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.","detailedDescription":"Double blind, randomized, controlled, Phase 2 clinical trial in hookworm-unexposed adults living in the metropolitan area of Washington, DC. Subjects will receive three doses of the assigned vaccine formulation, or saline placebo, delivered intramuscularly on approximately Days 0, 56, and 112.\n\nSubjects will be challenged with 50 infectious N. americanus larvae 4 weeks after 3rd vaccination. Fecal samples will be collected weekly starting 4 weeks post-challenge. Albendazole will be administered 20 weeks post-challenge to cure infections. Subjects will be followed until 10 months after their final vaccination.\n\nSafety of vaccination will be measured from the time of each study vaccination (Day 0) through 14 days after each study vaccination by the occurrence of solicited injection site and systemic reactogenicity events. Safety of CHHI will be measure from the time of larval application (Day 140) through the first day of treatment with albendazole (Day 280).\n\nUnsolicited non-serious adverse events (AEs) will be collected until approximately 1 month following each study vaccination and from study Day 140 (day of CHHI) through Day 280.\n\nNew-onset chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time of the first study vaccination through approximately 10 months after the third study vaccination (final visit). Clinical laboratory evaluations for safety will be performed on venous blood collected approximately 14 days after each vaccination and CHHI.\n\nImmunogenicity testing will include IgG antibody responses to Na-GST-1, by a qualified indirect enzyme-linked immunosorbent assay (ELISA), on serum obtained prior to each study vaccination and CHHI, and at time points after each vaccination and after CHHI (see Appendix A); the affinity of vaccine-induced antibodies against Na-GST-1 using Surface Plasmon Resonance; the functional activity of vaccine-induced antibodies via in vitro enzyme neutralization assay; antigen-specific memory B cell responses; and, the innate immune responses to each of the TLR receptor immunostimulants.\n\nParasitological testing will include microscopic fecal egg detection by a qualified saline flotation technique, fecal egg counts by the McMaster method, fecal PCR for hookworm DNA, and peripheral eosinophil counts.\n\nRecruitment and enrollment into the study will occur on an ongoing basis, with each group being recruited and vaccinated in sequence.\n\n48 subjects will be enrolled into 4 groups of 12. Subjects will be enrolled sequentially and upon enrollment will be randomized to one of the following IP assignments in a double-blind fashion:\n\n* Group 1 IP allocation (n=12 subjects): 12 subjects will receive 100µg Na-GST-1/Alhydrogel® delivered by IM injection in the deltoid muscle.\n* Group 2 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 500µg CpG 10104 delivered by IM injection in the deltoid muscle.\n* Group 3 IP allocation (n=12): 12 subjects will receive Na-GST-1/Alhydrogel® plus 5µg GLA-AF delivered by IM injection in the deltoid muscle.\n* Group 4 IP allocation (n=12): 12 subjects will receive sterile saline delivered by IM injection in the deltoid muscle."},"conditionsModule":{"conditions":["Hookworm Infections"],"keywords":["Controlled infection","Na-GST-1","Hookworm vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","maskingDescription":"Participants and investigators will be blinded to study product allocation.","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":39,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Na-GST-1/Alhydrogel","type":"EXPERIMENTAL","description":"100 µg Na-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","interventionNames":["Biological: Na-GST-1/Alhydrogel","Drug: Albendazole","Other: Necator americanus Larval Inoculum"]},{"label":"Na-GST-1/Alhydrogel + CPG 10104","type":"EXPERIMENTAL","description":"100 µg Na-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","interventionNames":["Biological: Na-GST-1/Alhydrogel + CPG 10104","Drug: Albendazole","Other: Necator americanus Larval Inoculum"]},{"label":"Na-GST-1/Alhydrogel + GLA-AF","type":"EXPERIMENTAL","description":"100 µg Na-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","interventionNames":["Biological: Na-GST-1/Alhydrogel + GLA-AF","Drug: Albendazole","Other: Necator americanus Larval Inoculum"]},{"label":"Saline Placebo","type":"PLACEBO_COMPARATOR","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","interventionNames":["Biological: Placebo","Drug: Albendazole","Other: Necator americanus Larval Inoculum"]}],"interventions":[{"type":"BIOLOGICAL","name":"Na-GST-1/Alhydrogel","description":"Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel","armGroupLabels":["Na-GST-1/Alhydrogel"],"otherNames":["Necator americanus Glutathione-S Transferase"]},{"type":"BIOLOGICAL","name":"Na-GST-1/Alhydrogel + CPG 10104","description":"Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide","armGroupLabels":["Na-GST-1/Alhydrogel + CPG 10104"]},{"type":"BIOLOGICAL","name":"Na-GST-1/Alhydrogel + GLA-AF","description":"Recombinant Necator americanus Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)","armGroupLabels":["Na-GST-1/Alhydrogel + GLA-AF"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Physiological sterile saline solution","armGroupLabels":["Saline Placebo"]},{"type":"DRUG","name":"Albendazole","description":"Treatment with 3 daily oral doses of 400 mg albendazole at end of study.","armGroupLabels":["Na-GST-1/Alhydrogel","Na-GST-1/Alhydrogel + CPG 10104","Na-GST-1/Alhydrogel + GLA-AF","Saline Placebo"]},{"type":"OTHER","name":"Necator americanus Larval Inoculum","description":"50 infectious Necator americanus larvae applied via dermal application (challenge infection).","armGroupLabels":["Na-GST-1/Alhydrogel","Na-GST-1/Alhydrogel + CPG 10104","Na-GST-1/Alhydrogel + GLA-AF","Saline Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Detectable Hookworm Infection","description":"Proportion of subjects with detectable hookworm eggs, at any time point, in fecal samples, as determined by microscopy using the qualified saline flotation technique","timeFrame":"On Study Days 175, 182, 189, 203, 217, 231, 245, 259, 273, and 280."},{"measure":"Incidence of Serious Adverse Events","description":"Frequency of study vaccine-related Serious Adverse Events from the time of the first study vaccination through approximately 10 months after the last study vaccination.","timeFrame":"Beginning on Day 0 when the first dose is received and ending on Day 380 (final study visit)."},{"measure":"Incidence of Solicited Injection Site and Systemic Reactogenicity","description":"Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.","timeFrame":"Dose 1: Days 0, 3, 7, 14; Dose 2: Days 56, 59, 63, 70; Dose 3: Days 112, 115, 119, 126"},{"measure":"Incidence of Solicited Adverse Events","description":"Frequency of solicited adverse events, graded by severity, on the day of CHHI through study Day 280","timeFrame":"Day of CHHI, Day 140, and study days: 143, 147, 154, 175, 182, 189, 196, 203, 210, 217, 224, 231, 238, 245, 252, 259, 266, 273, 280. Day 280 is the day of anti-worm treatment."},{"measure":"Incidence of Clinical Safety Laboratory Abnormalities","description":"Frequency of clinical safety laboratory adverse events.","timeFrame":"Study days: 0, 14, 56, 70, 112, 126, 140, 154, 175, 189, 203, 217, 231, 259, 280."},{"measure":"Incidence of Unsolicited Adverse Events","description":"Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination; and from the time of CHHI through treatment with albendazole (Day 280)","timeFrame":"From Dose 1 on Day 0 until anti-worm treatment on Day 280."},{"measure":"Incidence of New-onset Chronic Medical Conditions","description":"Frequency of new-onset chronic medical conditions through approximately 10 months after the third study vaccination.","timeFrame":"Entire duration of the study. Beginning Day 0, day of first dose, until Day 380, final study visit."},{"measure":"Incidence of Adverse Events of Special Interest","description":"Frequency of Adverse Events of Special Interest through approximately 10 months after the third study vaccination.","timeFrame":"Entire duration of the study. Beginning Day 0, day of first dose, until Day 380, final study visit."}],"secondaryOutcomes":[{"measure":"Fecal Egg Counts","description":"Fecal egg counts as determined by microscopy using the McMaster method, weekly from Weeks 5 through 20 post-CHHI","timeFrame":"Week 5 and Week 20 post-CHHI. Study days: 175, 182, 189, 203, 217, 231, 245, 259, 273, and 280."},{"measure":"Anti-Na-GST-1 IgG Antibody Response","description":"Anti-Na-GST-1 IgG antibody response as measured in Arbitrary Units per milliliter (AU/mL) of serum, determined by a qualified indirect enzyme-linked immunosorbent assay (ELISA) at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose. Levels of IgG antibodies against Na-GST-1 were converted to AUs by homologous interpolation of Optical Density readings at 492nm (OD492) from a standard calibration curve derived from serial dilutions of a human standard reference serum pool collected from high IgG responders (OD492 ≥ 1.000).","timeFrame":"Study days: 14, 70, 126, 140, 175, 189, 231, 280, 320, and 380"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and non-pregnant females between 18 and 45 years, inclusive.\n2. Good general health as determined by means of the screening procedures1.\n3. Available for the duration of individual subject study participation (14 months).\n4. Willingness to participate in the study as evidenced by signing the informed consent document.\n5. Able to understand and comply with planned study procedures.\n\nExclusion Criteria:\n\n1. Pregnancy as determined by a positive urine human choriogonadotropin (hCG) test (if female).\n2. Subject unwilling to use effective contraception for a minimum of 30 days prior to vaccination and up until documentation of clearance of hookworm infection post-CHHI (if female and not surgically sterile, abstinent from intercourse with a male partner, in a monogamous relationship with a vasectomized partner, at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile).\n3. Currently lactating and breast-feeding or plans to breastfeed at any given time from the first study vaccination until clearance of hookworm infection post-CHHI (if female).\n4. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, gastrointestinal, diabetes, or renal disease by history, physical examination, and/or laboratory studies.\n5. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide).\n6. Known or suspected immunodeficiency or immunosuppression as a result of an underlying illness or treatment (causes for immunosuppression may include, but are not limited to, poorly-controlled diabetes mellitus, chronic liver disease, renal insufficiency, active neoplastic disease or a history of hematologic malignancy, connective tissue disease, organ transplant).\n7. Laboratory evidence of liver disease (alanine aminotransferase \\[ALT\\] greater than 1.25-times the upper reference limit).\n8. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or urine dipstick testing positive for glucose or more than trace protein).\n9. Laboratory evidence of hematologic disease (hemoglobin \\<11.1 g/dl \\[females\\] or \\<12.5 g/dl \\[males\\]; absolute leukocyte count \\<3400/mm3 or \\>10.8 x 103/mm3; absolute eosinophil count \\<500/mm3; or platelet count \\<140,000/mm3).\n10. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.\n11. Planned participation in another investigational vaccine or drug trial within 30 days of starting this study or until the last study visit (this may include other licensed or unlicensed vaccines, drugs, biologics, devices, blood products, or medications).\n12. Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 24 months.\n13. Positive fecal occult blood test at screening.\n14. Infection with a pathogenic intestinal helminth as determined by stool examination for ova and parasites at screening.\n15. History of iron deficiency anemia or laboratory evidence of iron deficiency (serum ferritin concentration below the lower reference limit).\n16. History of hypoalbuminemia.\n17. History of a severe allergic reaction or anaphylaxis.\n18. Severe asthma as defined by the need for daily use of inhalers, or emergency clinic visit or hospitalization within 6 months of the volunteer's expected first vaccination in the study.\n19. Positive test for hepatitis B surface antigen (HBsAg).\n20. Positive confirmatory test for HIV infection.\n21. Positive confirmatory test for hepatitis C virus (HCV) infection.\n22. Using or intends to continue using oral or parenteral corticosteroids, high-dose inhaled corticosteroids (\\>800 μg/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs within 30 days of the volunteer's expected first vaccination in this study or planned use during the study.\n23. Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected first vaccination in the study.\n24. Receipt of immunoglobin or other blood products (with exception of Rho D immunoglobulin) within 90 days of the planned first study vaccination.\n25. Known allergy to albendazole, amphotericin B or gentamicin.\n26. History of previous infection with hookworm or continuous residence for more than 6 months in a community where hookworm is endemic.\n27. Current or past scars, tattoos, or other disruptions of skin integrity at the intended site of larval application.\n28. Previous receipt of the Na-GST-1/Alhydrogel® hookworm vaccine.\n29. History of a surgical splenectomy.\n30. Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosis, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia; or laboratory evidence of possible autoimmune disease determined by a positive anti-dsDNA titer, positive rheumatoid factor, and/or proteinuria (greater than trace protein on urine dipstick testing).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"David Diemert, MD","affiliation":"George Washington University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"George Washington University","city":"Washington D.C.","state":"District of Columbia","zip":"20037","country":"United States","geoPoint":{"lat":38.89511,"lon":-77.03637}}]},"referencesModule":{"references":[{"pmid":"41861834","type":"DERIVED","citation":"DiRosato CK, Malkin EM, Lee SM, Erwin G, Hoeweler L, Scholte L, Bottazzi ME, Pritchard DI, Hotez PJ, Bethony JM, Diemert DJ. Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, randomised controlled trial. Lancet Infect Dis. 2026 Jul;26(7):692-704. doi: 10.1016/S1473-3099(26)00018-6. Epub 2026 Mar 17."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"GW provided agreement with that NIAID that it will make publicly available all final research data resulting from this U01 clinical trial, in a timely fashion following closure of the clinical trial (not more than 12 months after the last subject follow-up visit). At no time will subject identifying information be made publically available.","infoTypes":["STUDY_PROTOCOL","ICF","CSR"],"timeFrame":"Within 12 months of final study visit.","accessCriteria":"To be determined."}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Recruitment and enrollment occurred on an ongoing basis, with each group being recruited and vaccinated in parallel. Participants were enrolled sequentially and upon enrollment were randomized to one of the four groups.","groups":[{"id":"FG000","title":"Na-GST-1/Alhydrogel","description":"100 µg Na-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"FG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg Na-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"FG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg Na-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"FG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"10"},{"groupId":"FG003","numSubjects":"8"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Na-GST-1/Alhydrogel","description":"100 µg Na-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"BG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg Na-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"BG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg Na-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"BG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"39"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.1","spread":"4.6"},{"groupId":"BG001","value":"30.4","spread":"8.2"},{"groupId":"BG002","value":"24.7","spread":"3.3"},{"groupId":"BG003","value":"26.1","spread":"3.45"},{"groupId":"BG004","value":"26.7","spread":"5.4"}]}]}]},{"title":"Age, Customized","paramType":"MEDIAN","dispersionType":"INTER_QUARTILE_RANGE","unitOfMeasure":"Years","classes":[{"title":"Age, Continuous","categories":[{"measurements":[{"groupId":"BG000","value":"25.5","lowerLimit":"19.0","upperLimit":"34.0"},{"groupId":"BG001","value":"29.0","lowerLimit":"21.0","upperLimit":"44.0"},{"groupId":"BG002","value":"23.5","lowerLimit":"21.0","upperLimit":"30.0"},{"groupId":"BG003","value":"25.5","lowerLimit":"22.0","upperLimit":"31.0"},{"groupId":"BG004","value":"26.0","lowerLimit":"19.0","upperLimit":"44.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"22"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"17"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Race","categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"5"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"3"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"25"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity","categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"7"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"32"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Detectable Hookworm Infection","description":"Proportion of subjects with detectable hookworm eggs, at any time point, in fecal samples, as determined by microscopy using the qualified saline flotation technique","populationDescription":"The number of participants analyzed each week varies due to participants missing that visit.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"On Study Days 175, 182, 189, 203, 217, 231, 245, 259, 273, and 280.","groups":[{"id":"OG000","title":"Group 1: Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Group 2: Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Group 3: Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Group 4: Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Day 175","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 182","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"}]}]},{"title":"Day 189","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Day 203","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"}]}]},{"title":"Day 217","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}]},{"title":"Day 231","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}]}]},{"title":"Day 245","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"}]}]},{"title":"Day 259","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"}]}]},{"title":"Day 273","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"}]}]},{"title":"Day 280","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"}]}]}]},{"type":"PRIMARY","title":"Incidence of Serious Adverse Events","description":"Frequency of study vaccine-related Serious Adverse Events from the time of the first study vaccination through approximately 10 months after the last study vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Beginning on Day 0 when the first dose is received and ending on Day 380 (final study visit).","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Solicited Injection Site and Systemic Reactogenicity","description":"Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.","populationDescription":"39 participants received the first dose of the study product, 37 participants received the second dose of the study product, and 36 participants received the third and final dose of the study product.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Dose 1: Days 0, 3, 7, 14; Dose 2: Days 56, 59, 63, 70; Dose 3: Days 112, 115, 119, 126","groups":[{"id":"OG000","title":"Group 1: Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Group 2: Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Group 3: Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Group 4: Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"title":"Number of Participants Reporting Solicited Adverse Events Post Dose #1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}]}]},{"title":"Number of Participants Reporting Solicited Adverse Events Post Dose #2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"}]}]},{"title":"Number of Participants Reporting Solicited Adverse Events Post Dose #3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}]}]},{"type":"PRIMARY","title":"Incidence of Solicited Adverse Events","description":"Frequency of solicited adverse events, graded by severity, on the day of CHHI through study Day 280","populationDescription":"Number of participants reporting solicited adverse events during CHHI phase of the study.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day of CHHI, Day 140, and study days: 143, 147, 154, 175, 182, 189, 196, 203, 210, 217, 224, 231, 238, 245, 252, 259, 266, 273, 280. Day 280 is the day of anti-worm treatment.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}]}]},{"type":"PRIMARY","title":"Incidence of Clinical Safety Laboratory Abnormalities","description":"Frequency of clinical safety laboratory adverse events.","populationDescription":"39 participants received at least 1 study vaccination and 33 participants received the CHHI.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Study days: 0, 14, 56, 70, 112, 126, 140, 154, 175, 189, 203, 217, 231, 259, 280.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"title":"Number of Participants reporting Clinical Laboratory Adverse Event during Vaccination Phase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}]},{"title":"Number of Participants reporting Clinical Laboratory Adverse Event during CHHI Phase","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}]}]},{"type":"PRIMARY","title":"Incidence of Unsolicited Adverse Events","description":"Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination; and from the time of CHHI through treatment with albendazole (Day 280)","populationDescription":"39 participants received Dose #1, 37 participants received Dose #2, 36 participants received Dose #3, and 33 participants received the CHHI.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Dose 1 on Day 0 until anti-worm treatment on Day 280.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"title":"Participants Reporting Unsolicited AEs up to 28 Days After Dose #1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"8"}]}]},{"title":"Participants Reporting Unsolicited AEs up to 28 Days After Dose #2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"}]}]},{"title":"Participants Reporting Unsolicited AEs up to 28 Days After Dose #3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"7"}]}]},{"title":"Participants Reporting Unsolicited AEs post-CHHI","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}]}]},{"type":"PRIMARY","title":"Incidence of New-onset Chronic Medical Conditions","description":"Frequency of new-onset chronic medical conditions through approximately 10 months after the third study vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Entire duration of the study. Beginning Day 0, day of first dose, until Day 380, final study visit.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events of Special Interest","description":"Frequency of Adverse Events of Special Interest through approximately 10 months after the third study vaccination.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Entire duration of the study. Beginning Day 0, day of first dose, until Day 380, final study visit.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Fecal Egg Counts","description":"Fecal egg counts as determined by microscopy using the McMaster method, weekly from Weeks 5 through 20 post-CHHI","populationDescription":"The number of participants analyzed each week varies due to participants missing that visits and/or that visit occurring too far out of window.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Eggs","timeFrame":"Week 5 and Week 20 post-CHHI. Study days: 175, 182, 189, 203, 217, 231, 245, 259, 273, and 280.","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"classes":[{"title":"Week 5 post-CHHI (Day 175)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"0.0","spread":"0.0"},{"groupId":"OG003","value":"0.0","spread":"0.0"}]}]},{"title":"Week 6 post-CHHI (Day 182)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"0.0","spread":"0.0"},{"groupId":"OG003","value":"4.2","spread":"11.8"}]}]},{"title":"Week 7 post-CHHI (Day 189)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"0.0","spread":"0.0"},{"groupId":"OG003","value":"10.4","spread":"23.5"}]}]},{"title":"Week 9 post-CHHI (Day 203)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"16.7"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"5.6","spread":"11.8"},{"groupId":"OG003","value":"31.0","spread":"58.1"}]}]},{"title":"Week 10 post-CHHI (Day 217)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"12.1"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"22.9","spread":"41.7"},{"groupId":"OG003","value":"38.9","spread":"62.9"}]}]},{"title":"Week 12 post-CHHI (Day 231)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"19.4"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"48.3","spread":"88.7"},{"groupId":"OG003","value":"29.6","spread":"58.8"}]}]},{"title":"Week 14 post-CHHI (Day 245)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"34.5"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"35.0","spread":"50.0"},{"groupId":"OG003","value":"14.6","spread":"30.1"}]}]},{"title":"Week 16 post-CHHI (Day 259)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"72.9"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"59.3","spread":"89.8"},{"groupId":"OG003","value":"31.0","spread":"29.5"}]}]},{"title":"Week 18 post-CHHI (Day 273)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"35.6"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"33.3","spread":"43.7"},{"groupId":"OG003","value":"38.1","spread":"48.8"}]}]},{"title":"Week 20 post-CHHI (Day 280)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":"23.2"},{"groupId":"OG001","value":"0.0","spread":"0.0"},{"groupId":"OG002","value":"35.4","spread":"52.3"},{"groupId":"OG003","value":"16.7","spread":"23.6"}]}]}]},{"type":"SECONDARY","title":"Anti-Na-GST-1 IgG Antibody Response","description":"Anti-Na-GST-1 IgG antibody response as measured in Arbitrary Units per milliliter (AU/mL) of serum, determined by a qualified indirect enzyme-linked immunosorbent assay (ELISA) at approximately 14 days after each vaccination, and approximately 1, 2, 4, 6, 7, 8 and 10 months after the third dose. Levels of IgG antibodies against Na-GST-1 were converted to AUs by homologous interpolation of Optical Density readings at 492nm (OD492) from a standard calibration curve derived from serial dilutions of a human standard reference serum pool collected from high IgG responders (OD492 ≥ 1.000).","populationDescription":"The number of participants analyzed each week varies due to participants missing that visits and/or that visit occurring too far out of window. Additionally, 39 participants received Dose 1, 37 participants received Dose 2, 36 participants received Dose 3, and 33 participants received the CHHI.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Arbitrary Units (AUs) per milliliter","timeFrame":"Study days: 14, 70, 126, 140, 175, 189, 231, 280, 320, and 380","groups":[{"id":"OG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."},{"id":"OG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"classes":[{"title":"Day 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.9"},{"groupId":"OG001","value":"1.4","spread":"0.0"},{"groupId":"OG002","value":"1.4","spread":"0.0"},{"groupId":"OG003","value":"1.7","spread":"1.0"}]}]},{"title":"Day 70 (14 days post Dose 2)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"1.1"},{"groupId":"OG001","value":"34.8","spread":"30.9"},{"groupId":"OG002","value":"26.7","spread":"65.5"},{"groupId":"OG003","value":"2.0","spread":"1.8"}]}]},{"title":"Day 126 (14 days post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":"32.4"},{"groupId":"OG001","value":"55.3","spread":"65.4"},{"groupId":"OG002","value":"18.7","spread":"23.3"},{"groupId":"OG003","value":"1.4","spread":"0.0"}]}]},{"title":"Day 140 (1 month post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"5.1"},{"groupId":"OG001","value":"31.0","spread":"29.5"},{"groupId":"OG002","value":"10.9","spread":"12.7"},{"groupId":"OG003","value":"2.2","spread":"2.3"}]}]},{"title":"Day 175 (2 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"5.2"},{"groupId":"OG001","value":"42.6","spread":"72.1"},{"groupId":"OG002","value":"7.7","spread":"7.9"},{"groupId":"OG003","value":"1.7","spread":"1.0"}]}]},{"title":"Day 189 (4 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"5.8"},{"groupId":"OG001","value":"26.3","spread":"28.4"},{"groupId":"OG002","value":"6.2","spread":"6.6"},{"groupId":"OG003","value":"2.2","spread":"2.3"}]}]},{"title":"Day 231 (6 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"4.4"},{"groupId":"OG001","value":"35.1","spread":"53.3"},{"groupId":"OG002","value":"5.2","spread":"5.8"},{"groupId":"OG003","value":"2.3","spread":"2.6"}]}]},{"title":"Day 280 (7 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"2.9"},{"groupId":"OG001","value":"21.6","spread":"26.7"},{"groupId":"OG002","value":"4.0","spread":"3.8"},{"groupId":"OG003","value":"2.4","spread":"2.6"}]}]},{"title":"Day 320 (8 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"3.0"},{"groupId":"OG001","value":"22.8","spread":"35.8"},{"groupId":"OG002","value":"3.8","spread":"3.1"},{"groupId":"OG003","value":"2.6","spread":"3.3"}]}]},{"title":"Day 380 (10 months post Dose 3)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"3.4"},{"groupId":"OG001","value":"110","spread":"11.6"},{"groupId":"OG002","value":"3.1","spread":"3.4"},{"groupId":"OG003","value":"2.3","spread":"2.3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"For the Vaccination phase, solicited AEs were collected from the day of study vaccination through 14 days after each study vaccination and unsolicited AEs were collected from the day of study vaccination through 28 days after each vaccination. For the CHHI phase, solicited adverse events were collected from day of hookworm larvae administration (day 140) through day 280, the day albendazole treatment and unsolicited AEs were collected from day 140 through day 297.","description":"During vaccination phase, solicited adverse events were collected via a participant completed paper symptom diary for 14 days following each vaccination. During CHHI phase, solicited adverse events were collected via a paper participant symptom diary which participants completed daily. The vaccination phase consisted of 39 participants (Group 1: 10, Group 2: 9, Group 3: 10, Group 4: 10) and the CHHI phase consisted of 32 participants (Group 1: 9, Group 2: 5, Group 3: 10, Group 4: 9).","eventGroups":[{"id":"EG000","title":"Na-GST-1/Alhydrogel","description":"100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG001","title":"Na-GST-1/Alhydrogel + CPG 10104","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":1,"seriousNumAtRisk":9,"otherNumAffected":9,"otherNumAtRisk":9},{"id":"EG002","title":"Na-GST-1/Alhydrogel + GLA-AF","description":"100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10},{"id":"EG003","title":"Saline Placebo","description":"Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.","deathsNumAffected":0,"deathsNumAtRisk":10,"seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":10,"otherNumAtRisk":10}],"seriousEvents":[{"term":"Hospitalization","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"Alcohol Intoxication","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":10}]}],"otherEvents":[{"term":"Brachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Dry Eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Lacrimation Increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Ocular Hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Abdominal Distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":10}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Injection Site Bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":3,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":10}]},{"term":"Injection Site Haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Ear Injection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":10}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Acrodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Oropharyngeal Gonococcal Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Ligament Sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Skin Abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"White Blood Cell Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Blood Pressure Diastolic Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Eosinophil Count Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"White Blood Cell Count Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Neutrophil Count Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Muscle Spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Musculoskeletal Chest Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Pain in Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Breast Tenderness","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Premenstrual Syndrome","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Dry Throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Nasal Dryness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":10}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":10},{"groupId":"EG001","numAffected":3,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Seborrhoeic Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":0,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Brachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Ocular Hyperaemia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Abdominal Distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Gastroesophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Apthous Ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Application Site Discolouration","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":7,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":9}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":3,"numAtRisk":5},{"groupId":"EG002","numAffected":5,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Corona Virus Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Post Viral Fatigue Syndrome","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Viral Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Syphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Vulvovaginal Mycotic Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Sunburn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Muscle Strain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Arthropod Bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Skin Abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Thermal Burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Blood Pressure Systolic Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Eosinophil Count Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":9},{"groupId":"EG001","numAffected":2,"numAtRisk":5},{"groupId":"EG002","numAffected":10,"numAtRisk":10},{"groupId":"EG003","numAffected":8,"numAtRisk":9}]},{"term":"White Blood Cell Count Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Blood Pressure Diastolic Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Haemoglobin Decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":3,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Blood Pressure Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Fluid Retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Back pain","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Arthralgia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":9}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Rhinorrhea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Nasal Congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":9}]},{"term":"Upper-airway Cough Syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Dermatitis Contact","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":3,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":9}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Rash Macular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":9}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":10},{"groupId":"EG001","numAffected":7,"numAtRisk":9},{"groupId":"EG002","numAffected":8,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":10}]},{"term":"Injection Site Tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":10},{"groupId":"EG001","numAffected":8,"numAtRisk":9},{"groupId":"EG002","numAffected":10,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":10}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Injection Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":10},{"groupId":"EG001","numAffected":2,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":10},{"groupId":"EG001","numAffected":8,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":8,"numAtRisk":10}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":4,"numAtRisk":9},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":10}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":1,"numAtRisk":9},{"groupId":"EG002","numAffected":0,"numAtRisk":10},{"groupId":"EG003","numAffected":0,"numAtRisk":10}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":5,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":10},{"groupId":"EG001","numAffected":4,"numAtRisk":9},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":10}]},{"term":"Application Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":1,"numAtRisk":9}]},{"term":"Application Site Tenderness","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":2,"numAtRisk":10},{"groupId":"EG003","numAffected":2,"numAtRisk":9}]},{"term":"Application Site Rash","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":9},{"groupId":"EG001","numAffected":2,"numAtRisk":5},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Application Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":4,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":9}]},{"term":"Application Site Pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":9},{"groupId":"EG001","numAffected":5,"numAtRisk":5},{"groupId":"EG002","numAffected":5,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":9},{"groupId":"EG001","numAffected":3,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":5,"numAtRisk":9}]},{"term":"Abdominal Bloating","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":9},{"groupId":"EG001","numAffected":3,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":5,"numAtRisk":9}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":9},{"groupId":"EG001","numAffected":3,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":9}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":3,"numAtRisk":9}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":6,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":9},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":7,"numAtRisk":10},{"groupId":"EG003","numAffected":6,"numAtRisk":9}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":9},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]},{"term":"Oropharyngeal Pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"CHHI Phase","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":9},{"groupId":"EG001","numAffected":2,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":10},{"groupId":"EG003","numAffected":4,"numAtRisk":9}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"David J. Diemert, MD","organization":"George Washington University","email":"ddiemert@gwu.edu","phone":"202-994-2909"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2025-10-03","uploadDate":"2025-11-18T12:11","filename":"Prot_002.pdf","size":5789889},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-06-15","uploadDate":"2025-09-08T11:53","filename":"SAP_001.pdf","size":553730}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-09-26","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D006725","term":"Hookworm Infections"}],"ancestors":[{"id":"D017206","term":"Strongylida Infections"},{"id":"D017190","term":"Secernentea Infections"},{"id":"D009349","term":"Nematode Infections"},{"id":"D006373","term":"Helminthiasis"},{"id":"D010272","term":"Parasitic Diseases"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D015766","term":"Albendazole"}],"ancestors":[{"id":"D002219","term":"Carbamates"},{"id":"D000144","term":"Acids, Acyclic"},{"id":"D002264","term":"Carboxylic Acids"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D001562","term":"Benzimidazoles"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}